Onyx Biotec Itemizing: Onyx Biotec made a weak market debut on Friday, November 22 as its shares have been listed at ₹54 every on NSE SME, an 11.50% low cost to the problem value of ₹61. Nonetheless, post-listing, the inventory recovered a bit and jumped 5% to achieve ₹56.75.
The SME IPO, valued at ₹29.34 crore, was open for subscription from November 13 to November 18, 2024, with a value band of ₹58 to ₹61 apiece.
The problem noticed a strong response from traders, being oversubscribed 198 occasions. Particularly, the non-institutional phase was oversubscribed 602 occasions, whereas the retail investor portion was oversubscribed 118 occasions. The QIB portion was booked 32.49 occasions, as per the alternate information.
The corporate intends to make use of the web proceeds from the IPO for a number of functions, akin to upgrading its present Manufacturing Unit I to supply large-volume parenteral for intravenous use, establishing a high-speed carton packaging line at its present Manufacturing Unit II for dry powder injections, prepaying or repaying a part of its excellent loans, and for basic company functions.
About Onyx Biotec
The corporate is a pharmaceutical firm offering sterile water for injections. It at present manufactures sterile water for injections and serves as a pharmaceutical contract producer, providing a complete vary of dry powder injections and dry syrups for each the Indian and abroad markets.
The corporate has two state-of-the-art manufacturing services positioned in Himachal Pradesh. Its manufacturing facility Unit I has a manufacturing capability of 6,38,889 items of sterile water for injections per day, and Unit II has a capability of 40,000 items of dry powder injection per day and 26,667 items of dry syrup per day in a single shift.
As of Might 31, 2024, the corporate’s key shoppers embody Hetero Healthcare Restricted, Mankind Pharma Restricted, Solar Pharmaceutical Industries Restricted, Aristo Prescription drugs Non-public Restricted, Macleods Prescription drugs Restricted, Mapra Laboratories Non-public Restricted, Axa Parenterals Restricted, FDC Restricted, Zuventus Healthcare Restricted, Akums Medication and Prescription drugs Restricted, and Reliance Life Sciences Restricted, amongst others, as per the corporate’s DRHP report.
